Skip to main content
OpenTrials
Completed

NCT Number: NCT01595360

Safety, Tolerability and Efficacy Study of TT-173 in Healthy Volunteers After Tooth Extraction

The purpose of this study is to evaluate the safety, tolerability and efficacy of TT-173 in healthy volunteers after tooth extraction.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Thrombotargets Europe SL

Castelldefels, Barcelona, 08860, Spain

About this study

As the TT-113 has been cleared for use as a topical hemostatic agent, the proposed study will further investigate the safety, tolerability and efficacy of TT-113 in healthy volunteers after tooth extraction.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects to be undertaken for the simple extraction of at least one tooth (incisor, canine, premolar, molar different of third molar) that cause bloody wound, located in the upper or inferior maxillary area of the mouth either
  • Subjects who are able and willing to provide written and signed informed consent
  • All subjects willing to use a medically accepted form of contraception from the time of consent to completion of all follow-up study visits. Negative pregnancy test result in the screening visit.

Exclusion criteria

  • Subjects with personal and family history that could affect correct hemostasis
  • Subjects with any clinically-significant coagulation disorder including including deficiencies in any of coagulation factors, thrombocytopenia and vascular purpura
  • Subject with hipersensivity of TT-173 of any of its components or has a known allergy.
  • Subjects who are unable to adequately follow or understand the instructions and requirements of the study.
  • Subjects that are not fully free to give informed consent, or any other obstacle in the opinion of investigator support the conclusion that the subject is not fully reasoned.

Treatment and study plan

Placebo

Drug

It is applied directly to the bleeding site after tooth extraction

TT-173

Drug

It is applied directly to the bleeding site after tooth extraction

Primary outcomes

  1. Number of Adverse Events

    Time frame: 4 months

Secondary outcomes

  1. Cmax, Tmax, AUC and bioavailability

    Time frame: 48 h

  2. Determine the presence of coagulation disorders

    Time frame: 4 months

    Blood platelets, Prothrombin time, Fibrinogen, Thrombin time

  3. Determine the immune responses to TT-173

    Time frame: 4 months

    Antibody concentration

  4. Time to hemostasis until cessation of bleeding

    Time frame: time 0 until cessation of bleeding

Sponsors and collaborators

Lead sponsor

Thrombotargets Europe S.L

Industry

Registry information

Official study title

A Phase 1, Randomized, Open, Controlled, Comparative Safety, Tolerability and Efficacy Study of TT-173 in Healthy Volunteers After Tooth Extraction

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
May 10, 2012
Registry last updated
Sep 16, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.